Plasma Metabolomic Profiles Differentiate Patients With Dilated Cardiomyopathy and Ischemic Cardiomyopathy

Junhan Zhao, Shengwen Yang, Ran Jing, Han Jin, Yiran Hu, Jing Wang, Min Gu, Hongxia Niu, Shu Zhang, Liang Chen, Wei HuaFrontiers in Cardiovascular Medicine 2020 · DOI

Abstract

Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) are common causes of heart failure (HF). Though they share similar clinical characteristics, their differential effects on cardiovascular metabolomics have yet to be elucidated. In this study, we applied a comprehensive metabolomics platform to plasma samples of HF patients with different etiology (38 patients with DCM and 18 patients with ICM) and 20 healthy controls. Significant differences in metabolomics profiling were shown among two cardiomyopathy groups and healthy controls. Two hundred thirty three dysregulated metabolites were identified between DCM vs. healthy controls, and 204 dysregulated metabolites between ICM patients and healthy controls. They have 140 metabolites in common, with fold-changes in the same direction in both groups. Pathway analysis found the commonalities of HF pathways as well as disease-specific metabolic signatures. In addition, we found that a combination panel of 6 metabolites including 1-pyrroline-2-carboxylate, norvaline, lysophosphatidylinositol (16:0/0:0), phosphatidylglycerol (6:0/8:0), fatty acid esters of hydroxy fatty acid (24:1), and phosphatidylcholine (18:0/18:3) may have the potential to differentiate patients with DCM and ICM.

Introduction

Heart failure (HF) represents the terminal stage of various cardiovascular conditions, yet its underlying causes are heterogeneous. Two primary etiologies are Dilated Cardiomyopathy (DCM), often linked to genetic factors or inflammation, and Ischemic Cardiomyopathy (ICM), resulting from coronary artery disease. While these conditions present with overlapping clinical symptoms such as dyspnea and fatigue, their pathophysiology differs significantly. Currently, differentiating between DCM and ICM often necessitates invasive procedures like coronary angiography. There is a critical need for non-invasive "liquid biopsies"—blood-based metabolic tests—to distinguish these etiologies, enabling more personalized treatment strategies and improved prognostic assessments.

Study Design and Methodology

This study utilized an untargeted metabolomics approach to capture a broad spectrum of small-molecule metabolites in plasma samples. The cohort consisted of 76 participants from Fuwai Hospital in Beijing, including 38 DCM patients, 18 ICM patients, and 20 healthy controls.

Figure 1: Study workflow and participant selection process.

Plasma samples were analyzed using Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS). Statistical modeling, including Principal Component Analysis (PCA) and Partial Least Squares Discriminant Analysis (PLS-DA), was employed to identify group-specific metabolic clusters. To isolate the most robust biomarkers, the researchers applied LASSO (Least Absolute Shrinkage and Selection Operator) regression, narrowing hundreds of candidates down to a final six-metabolite panel.

Metabolic Signatures of Heart Failure

The analysis revealed a "core" metabolic signature of heart failure, with 140 metabolites dysregulated in both DCM and ICM compared to healthy controls. These commonalities suggest shared pathways of disease progression, such as impaired TCA cycle function and elevated oxidative stress.

Figure 2: Venn diagram illustrating common and etiology-specific dysregulated metabolites in ESI- mode.

Despite these overlaps, distinct metabolic fingerprints emerged for each condition. DCM was specifically associated with alterations in alpha-linolenic acid metabolism, whereas ICM showed stronger links to linoleic acid and arginine biosynthesis. Notably, 1-pyrroline-2-carboxylate was significantly lower in DCM patients, suggesting a potentially compromised ability to manage redox balance compared to ICM patients.

Diagnostic Performance

The study identified 233 dysregulated metabolites in DCM vs. controls and 204 in ICM vs. controls. The optimized 6-metabolite panel—comprising norvaline, 1-pyrroline-2-carboxylate, and specific lipids (LysoPI, PG, FAHFA, and PC)—demonstrated exceptional discriminatory power. The model achieved an Area Under the Curve (AUC) of 0.97, with a diagnostic accuracy of 95% in the training set and 87% in the testing set. PLS-DA plots further confirmed that DCM, ICM, and healthy controls formed distinct, non-overlapping metabolic clusters.

Limitations and Future Directions

While promising, several limitations must be addressed before clinical implementation. The study's sample size, particularly for the ICM group, was relatively small. Furthermore, as a single-center study conducted in Beijing, the results may be influenced by regional dietary and environmental factors. Future research should involve larger, multi-center cohorts to validate these biomarkers across diverse populations. Additionally, while plasma metabolomics offers a non-invasive diagnostic tool, it reflects systemic changes; further studies integrating cardiac tissue analysis could provide deeper insights into the localized metabolic shifts within the failing heart.

Summary updated

Abstract

Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) are common causes of heart failure (HF). Though they share similar clinical characteristics, their differential effects on cardiovascular metabolomics have yet to be elucidated. In this study, we applied a comprehensive metabolomics platform to plasma samples of HF patients with different etiology (38 patients with DCM and 18 patients with ICM) and 20 healthy controls. Significant differences in metabolomics profiling were shown among two cardiomyopathy groups and healthy controls. Two hundred thirty three dysregulated metabolites were identified between DCM vs. healthy controls, and 204 dysregulated metabolites between ICM patients and healthy controls. They have 140 metabolites in common, with fold-changes in the same direction in both groups. Pathway analysis found the commonalities of HF pathways as well as disease-specific metabolic signatures. In addition, we found that a combination panel of 6 metabolites including 1-pyrroline-2-carboxylate, norvaline, lysophosphatidylinositol (16:0/0:0), phosphatidylglycerol (6:0/8:0), fatty acid esters of hydroxy fatty acid (24:1), and phosphatidylcholine (18:0/18:3) may have the potential to differentiate patients with DCM and ICM.
BibTeX
@inproceedings{zhao2020plasma,
  author = {Junhan Zhao and Shengwen Yang and Ran Jing and Han Jin and Yiran Hu and Jing Wang and Min Gu and Hongxia Niu and Shu Zhang and Liang Chen and Wei Hua},
  title = {{Plasma Metabolomic Profiles Differentiate Patients With Dilated Cardiomyopathy and Ischemic Cardiomyopathy}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2020},
  doi = {10.3389/fcvm.2020.597546},
}
Figure